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Alprostadil is a prostaglandin E1 analogue (PGE1
a-cyclodextrin clathrate) used in neonates to main-
tain a patent ductus arteriosus in cases of ductal-
dependent congenital heart disease (CHD).1 PGE1 is
critical in sustaining oxygen saturation in these
patients while awaiting surgical repair or cardiac
transplant. Despite being reasonably well tolerated,
a review of 62 neonates with CHD treated with PGE1
suggested a range of adverse events, most commonly
including central nervous system events (16%),
respiratory depression (12%), and cardiovascular
complications (18%).2
Cutaneous flushing and peripheral edema are
well-recognized side effects of PGE1 infusion,2
although there is a paucity of data with regard to
cutaneous adverse events. A search of the literature
found 4 other cutaneous reactions reported,
including harlequin color change, urticaria, and
subcutaneous fat necrosis of the newborn.3-5 We
present a case of an extensive and striking polycyclic
eruption associated with PGE1 administration in a
2-day-old neonate and highlight the importance of
recognizing this entity to avoid delay in diagnosis
and unnecessary interventions.CASE REPORT
A full-term male neonate with prenatally diag-
nosed severe congenital diaphragmatic hernia was
intubated at birth and transferred to our institution for
surgical management of the condition and extracor-
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before ECMO was significant for dilated right-sided
cardiac structures and a large patent ductus arteriosus
with right-to-left shunt. The patient’s medications
included dopamine, sildenafil, alprostadil, fentanyl,
ampicillin, gentamycin, and heparin.
On day 3 of life, a widespread erythematous
eruption developed on the patient’s trunk and
extremities for which the dermatology department
was consulted. The eruption was minimally respon-
sive to diphenhydramine. Examination found
brightly erythematous annular and polycyclic
patches on the face, trunk, and extremities, which
were noted to migrate throughout the day, some-
times within minutes (Fig 1). There was periungual
erythema of similar quality, and the upper eyelids
were erythematous and edematous. Mucous mem-
branes were intact. The patient was afebrile. The
differential diagnosis included urticaria, drug erup-
tion, or an urticarial eruption associated with an
autoinflammatory syndrome such as neonatal-onset
multisystem inflammatory disease. Skin biopsy was
offered but declined by the family.
Because of the possibility of a drug reaction, close
observation was performed over the ensuing
24 hours, and the rash appeared to be exacerbatedJAAD Case Reports 2016;2:377-9.
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Fig 1. Migratory polycyclic eruption occurring after of
PGE1 administration in a neonate.
Fig 2. Resolution of eruption shortly after discontinuation
of PGE1.
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connection, PGE1 was held on day 4 of life with
complete resolution of the rash within minutes of
discontinuation (Fig 2). To further support this
association, alprostadil was rapidly restarted, with
immediate recurrence of the rash. Given the unclear
significance of this widespread eruption, PGE1 was
discontinued. However, flow rates on ECMO were
compromised immediately after removal of PGE1;
on day 8 of life PGE1 was reinitiated, interestingly
without recurrence of the rash.
DISCUSSION
In this case, a 2-day-old neonate experienced a
migratory, annular cutaneous eruption after admin-
istration of PGE1. To our knowledge, this is a very
rare reported side effect of PGE1 administration, with
1 similar case reported in the literature.3
Dermatologic complications after PGE1 adminis-
tration are currently poorly characterized, particularly
in pediatric cohorts. A review of the literature found 4
reports of cutaneous reactions after PGE1 administra-
tion for CHD, including harlequin color change, urti-
caria, and subcutaneous fat necrosis of the newborn,3-
5 with all instances occurring in neonates. Carter and
Garzon3 described a migratory polycyclic erythema
after starting alprostadil in a neonate, and biopsy in
this case was consistent with urticaria. A review of
pediatric annular lesions by Nopper et al6 noted the
occurrence of transient annular erythema in neonates
receiving intravenous prostaglandins, whereas Raoet al4 reported harlequin color change in 3 neonates
associated with PGE1 administration.
PGE1 is proposed to induce cutaneous inflamma-
tion via vasodilation, leading to local edema and
hyperemia. Interestingly, the reported case lacked
an edematous component. The severity of the
response—both in this and prior cases3—was directly
correlated with the amount of PGE1 administered.
This finding suggests a nonallergic mechanism, as
allergic responses generally do not exhibit a direct
dose-response relationship, with even minimal
quantities inducing life-threatening symptoms.
Administration of PGE1 may elicit vasodilation via
a nonallergic pathway of histamine release analo-
gous to the ‘‘red man syndrome’’ of vancomycin,7 an
anaphylactoid reaction that induces direct degranu-
lation of mast cells and basophils without preformed
IgE or complement. Factors known to modulate
severity of red man syndrome include dose and
rate of infusion, with severity generally improving
with slower infusion.8 A number of experimental
trials found PGE1’s ability to trigger release of hista-
mine from mast cells and basophils and elicit dose-
correlative cutaneous events.7,8 These events may
also be analogous to nonallergic urticaria in which
mast cells undergo direct degranulation, a process
well described with medications including opioids
and nonsteroidal anti-inflammatory drugs.9
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cause a dose-dependent wheal and flare reaction, the
wheal—but not the flare—is suppressed by antihista-
minepretreatment.8 This finding argues that histamine
is unlikely to be the sole mediator in the pathogenesis
of this reaction, further suggesting that PGE1 may
lead to vasodilation and cutaneous inflammation via
concurrent mechanisms independent of histamine, as
in bradykinin-induced angioedema. Newer data sug-
gest involvement of the coagulation cascade in the
pathogenesis of chronic urticaria, with thrombin
inducing mast cell activation and production of
anaphylatoxin C5a.10,11 Metz et al12 have also
described increased levels of neuropeptide substance
P in patients with chronic urticaria. It is not known if
PGE1 may alter these pathways. Notably, our patient
did not benefit from treatment with diphenhydra-
mine, which aligns with the findings in previously
reported cases and further argues against a pathogen-
esis solely related to histamine.8
Neonatal hypoxia has been proposed to underlie
the pathogenesis of harlequin color change13 and
subcutaneous fat necrosis of the newborn. PGE1 is
administered to infants with cyanotic CHD.1 Overall,
this finding may suggest an underlying theme in
which hypoxic events early in life engender a pre-
disposition toward aberrant vasodilatory cutaneous
reactions in these patients, which may also involve
thrombin and alteration of the coagulation
cascade.11,12
A migratory, polycyclic erythema may occur in
neonates exposed to PGE1. In particular, this symp-
tomology seems to accompany hypoxia in the setting
of CHD, and we hypothesize that previously re-
ported cases of harlequin color change and urticaria
may also represent aberrant vasodilatory responses.
Recognition of this striking cutaneous side effect
allows for expedient diagnosis and avoidance ofunnecessary interventions. Given the lack of sys-
temic sequelae thus far reported, interruption of
treatment may not be necessary in all cases and
continuation carefully considered when PGE1 is a
life-sustaining therapy. Future studies may lead to
additional corroboration and greater understanding
of the biochemical mechanism of this obscure event.REFERENCES
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